| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
ROTTERDAM, Netherlands—In late October, Spotfire Inc. announced it entered into a three-year relationship with the Erasmus University Medical Center, based here, to provide it with DecisionSite business analytics software and consultation services as Erasmus looks to establish its own bioinformatics discipline. The project is led by the bioinformatics department unit of Erasmus Medical Center under the leadership of Prof. Peter Van der Spek.
 
"Spotfire visual analytics software enables scientists to integrate complex molecular and clinical data and gain insight in molecular processes underlying disease," says Van der Spek of the decision to work with Spotfire. Using this information, Erasmus researchers will initially look to gain a better understanding of biomarker behavior to monitor the progression of disease and to potentially provide treatment strategies.
 
"Professor Van der Spek knows Spotfire quite well and has used it for quite a long time in his work at pharmaceutical companies," says Christian Marcazzo, senior director of life science marketing at Spotfire. "He recognizes the potential that Spotfire holds in being able to integrate all the different data sources and analysis tools that are necessary on a broad scale to look at and identify biomarkers. Spotfire is the only tool where a scientist could look at SNP data, transcript data, genomic data, gene function data and proteomic data in one environment and be able to do analyses across all those different data sources."
 
As part of the three-year agreement, Spotfire has agreed to work with Erasmus in the development of tools and "guided analytic applications" for biomarkers, pathways visualization, bioinformatics and integration with other data sources. It will help train Erasmus students in the use of its software to help them gain more insight into how to use advanced visualizations in their research and will also investigate the deployment of visualization methods in clinical research and diagnostics.
 
"Important for us, too, is Erasmus will provide us with a lot of hands-on learning about how they apply software to the field of biomarker discovery, which I believe is one of the next phases of growth for Spotfire in life sciences," says Marcazzo. "From this collaboration I hope that we can learn what improvements we can make in DecisionSite or DecisionSite for Functional Genomics to help scientists more quickly analyze their data and make discoveries in it."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue